All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
H.C. Wainwright Maintains Enlivex Therapeutics(ENLV.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright analyst Ram Selvaraju maintains $Enlivex Therapeutics(ENLV.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 40
Enlivex Therapeutics Financials Indicate Net Loss
Enlivex Therapeutics Price Target Announced at $13.00/Share by EF Hutton
EF Hutton Initiates Coverage On Enlivex Therapeutics With Buy Rating, Announces Price Target of $13
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients With Thumb Osteoarthritis
Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Enlivex Therapeutics Releases Interim Data Readout From Phase I/II AllocetraTM Trial Showing; Three-Month Readout Showed Avg. Pain Reduciotn Of 64%, 33% Of Patients Reported Pain Resolution, 89% Of Patients Did Not Proceed With Knee Replacement Surgery
H.C. Wainwright Maintains Enlivex Therapeutics(ENLV.US) With Buy Rating, Cuts Target Price to $6
H.C. Wainwright analyst Ram Selvaraju maintains $Enlivex Therapeutics(ENLV.US)$ with a buy rating, and adjusts the target price from $7 to $6.According to TipRanks data, the analyst has a success rate
Enlivex Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Enlivex Therapeutics Ltd : H.c. Wainwright Cuts Target Price to $6 From $7
HC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Lowers Price Target to $6
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients With Thumb Osteoarthritis
Enlivex Therapeutics Announces New Securities Deal
Enlivex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering